+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Tumor inhibition by metallocenes: antitumor activity of titanocene dihalides (C5H5)2TiX2 (X=F, Cl, Br, I, NCS) and their application in buffered solutions as a method for suppressing drug-induced side effects



Tumor inhibition by metallocenes: antitumor activity of titanocene dihalides (C5H5)2TiX2 (X=F, Cl, Br, I, NCS) and their application in buffered solutions as a method for suppressing drug-induced side effects



Journal of Cancer Research and Clinical Oncology 97(1): 31-39



The antitumor activity of titanocene dihalides (C5H5)2TiX2 with X=F, Cl, Br, I, NCS is investigated against Ehrlich ascites tumor in CF 1 mice. Varying doses of the compounds are applied as single i.p. injections 24 h p.t.t. both in non-buffered (pH 1.4-3.9) and buffered (pH 4.2-5.9) solutions or suspensions, all of the substances achieving in optimum doses cure rates of 100% on day 120 p.t.t. This corresponds to I.L.S. values of 600-750% referred to the untreated controls. Some drug-induced side effects, especially the appearance of postperitonitic symptoms several weeks after i.p. application of higher doses of titanocene dihalides, are strikingly reduced by pH elevation in the injected drug solutions.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 044875898

Download citation: RISBibTeXText

PMID: 7400205


Related references

Tumor inhibition by metallocenes anti tumor activity of titanocene di halides and their application in buffered solutions as a method for suppressing drug induced side effects. Journal of Cancer Research & Clinical Oncology 97(1): 31-40, 1980

Tumor inhibition by metallocenes: effect of titanocene, zirconocene, and hafnocene dichlorides on Ehrlich ascites tumor in mice. Journal of Cancer Research and Clinical Oncology 96(1): 43-51, 1980

Anti tumor activity of metallocenes substituted or bridged titanocene di chlorides. European Journal of Medicinal Chemistry 16(3): 275-281, 1981

Tumor necrosis factor: how to improve the antitumor activity and decrease accompanying side effects for therapeutic application. Journal of Biological Response Modifiers 7(6): 525-534, 1988

Effects of methylxanthine derivatives on antitumor activity and toxic side effect of adriamycin induced by inhibition of DNA biosynthesis. Yakugaku Zasshi 118(5): 179-187, 1998

Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3(1): 1351-1371, 2011

Activity of titanocene dihalides against a human colon carcinoma heterotransplanted to athymic mice. European Journal of Cancer & Clinical Oncology 21(7): 853-858, 1985

Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice. Anti-Cancer Drugs 18(3): 311-315, 2007

Effects of buffered 2.3%, buffered 0.9%, and non-buffered 0.9% irrigation solutions on nasal mucosa after septoplasty. European Archives of Oto-Rhino-Laryngology 266(5): 685-689, 2009

Tumor inhibition by titanocene complexes: activity against sarcoma 180. Anticancer Research 6(1): 33-37, 1986

Effects of antibiotic antitumor drugs on nucleotide levels in cultured tumor cells: an exploratory method to distinguish the mechanisms of antitumor drug action based on targeted metabolomics. Acta Pharmaceutica Sinica. B 5(3): 223-230, 2015

Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. International Journal of Cancer 81(4): 560-567, 1999

Tumor inhibition by metallocenes: activity against leukemias and detection of the systemic effect. European Journal of Cancer 17(6): 665-669, 1981

Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma. Arzneimittel-Forschung 37(5): 532-534, 1987

Inhibition of human topoisomerase II by the antitumor metallocenes. Journal of Inorganic Biochemistry 83(2-3): 205-209, 15 January, 2001